Armodafinil is a medication used to promote wakefulness in individuals suffering from sleep-related disorders such as Narcolepsy, Obstructive Sleep Apnea, and Shift Work Sleep Disorder. It is the R-enantiomer of Modafinil, meaning it represents the longer-acting and more active component of modafinil, resulting in sustained alertness and improved daytime functioning. The drug acts on the central nervous system by affecting neurotransmitters that regulate the sleep–wake cycle, although its precise mechanism of action is still not completely understood. The origin of armodafinil can be traced back to research on modafinil, which was first developed in France in the 1970s by Lafon Laboratories. Scientists later identified that modafinil consisted of two mirror-image forms (enantiomers), and further studies showed that the R-enantiomer had a longer half-life and greater efficacy. This discovery led to the development of armodafinil as a separate drug, which was subsequently approved in 2007 by the U.S. Food and Drug Administration and marketed under the brand name Nuvigil. Since then, it has become an important therapeutic option for managing excessive sleepiness and continues to be explored for additional clinical and off-label applications.
